美股异动丨赛诺菲盘前大跌超9%，OX40L数据不及预期

Core Viewpoint - Sanofi (SNY.US) experienced a pre-market drop of over 9%, trading at $45.35, following the announcement that the Phase III COAST 1 study of Amlitelimab for atopic dermatitis met all primary and secondary endpoints, but the results fell short of market expectations [1] Group 1: Company Overview - Amlitelimab is a fully human non-T cell depleting monoclonal antibody targeting OX40L (OX40 ligand), developed by Sanofi [1] - The drug functions by blocking the interaction between the key immune regulatory factor OX40L and its receptor OX40, maintaining the balance between pro-inflammatory T cells and regulatory T cells [1] - Amlitelimab is currently the only OX40L antibody in Phase III development [1] Group 2: Market Reaction - The market reacted negatively to the study results, leading to a significant decline in Sanofi's stock price [1] - The results of the COAST 1 study did not meet the expectations set by market analysts, contributing to the stock's drop [1]